Tumors consist of both the actual, malignant cancer cells and healthy, non-transformed cells in the immediate environment.
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases,